SG10201406571YA - Pharmaceutical compositions - Google Patents
Pharmaceutical compositionsInfo
- Publication number
- SG10201406571YA SG10201406571YA SG10201406571YA SG10201406571YA SG10201406571YA SG 10201406571Y A SG10201406571Y A SG 10201406571YA SG 10201406571Y A SG10201406571Y A SG 10201406571YA SG 10201406571Y A SG10201406571Y A SG 10201406571YA SG 10201406571Y A SG10201406571Y A SG 10201406571YA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25102309P | 2009-10-13 | 2009-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201406571YA true SG10201406571YA (en) | 2014-11-27 |
Family
ID=43876821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201406571YA SG10201406571YA (en) | 2009-10-13 | 2010-10-12 | Pharmaceutical compositions |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20120208857A1 (ko) |
| EP (2) | EP2488175A4 (ko) |
| JP (3) | JP2013507443A (ko) |
| KR (1) | KR101791709B1 (ko) |
| CN (1) | CN102573840A (ko) |
| AU (2) | AU2010307054A1 (ko) |
| BR (1) | BR112012008649A2 (ko) |
| CA (1) | CA2776310A1 (ko) |
| EA (1) | EA022765B1 (ko) |
| IL (1) | IL219018A (ko) |
| MX (1) | MX337145B (ko) |
| NZ (1) | NZ599151A (ko) |
| SG (1) | SG10201406571YA (ko) |
| UA (1) | UA111145C2 (ko) |
| WO (1) | WO2011046905A2 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101944124B1 (ko) * | 2010-11-24 | 2019-01-30 | 멜린타 서브시디어리 코프. | 약학 조성물 |
| CN104784113B (zh) * | 2015-04-30 | 2017-09-29 | 成都国为生物医药有限公司 | 一种含有利奈唑胺的组合物及其制备方法 |
| US11112370B2 (en) * | 2019-01-04 | 2021-09-07 | The Boeing Company | Reconfigurable backscatter detector |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5688792A (en) * | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
| MY127336A (en) * | 2000-03-22 | 2006-11-30 | Upjohn Co | Container for linezolid iv solution |
| PE20011088A1 (es) * | 2000-03-22 | 2001-10-04 | Upjohn Co | Tratamiento de infecciones del tracto urinario con oxazolidinonas antibacterianas |
| MXPA02012045A (es) | 2000-06-05 | 2003-10-15 | Dong A Pharm Co Ltd | Nuevos derivados de oxazolidinona y proceso para su preparacion. |
| PE20020300A1 (es) * | 2000-08-22 | 2002-05-10 | Pharmacia Corp | Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco |
| US6696426B2 (en) * | 2000-08-22 | 2004-02-24 | Pharmacia Corporation | Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems |
| MY137618A (en) * | 2000-08-22 | 2009-02-27 | Pharmacia Corp | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading |
| TWI378092B (en) | 2003-06-03 | 2012-12-01 | Rib X Pharmaceuticals Inc | Biaryl heterocyclic compounds and methods of making and using the same |
| WO2005070904A2 (en) * | 2003-06-03 | 2005-08-04 | Rib-X Pharmaceutical, Inc. | Sulfonamide compounds and methods of making and using the same |
| WO2005061468A1 (en) | 2003-12-17 | 2005-07-07 | Rib-X Pharmaceuticals, Inc. | Halogenated biaryl heterocyclic compounds and methods of making and using the same |
| KR100854211B1 (ko) | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
| US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US7696211B2 (en) * | 2005-04-29 | 2010-04-13 | Wilson Constance N | Methods and pharmaceutical compositions for treating sepsis |
| US20070249577A1 (en) * | 2005-05-10 | 2007-10-25 | Hopkins Scott J | Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures |
| WO2007086011A1 (en) * | 2006-01-25 | 2007-08-02 | Jegannathan Srinivas | Formulation comprising cefepime, tazobactam and linezolid |
| WO2007133803A2 (en) * | 2006-05-15 | 2007-11-22 | Rib-X Pharmaceuticals, Inc. | Treatment of mycobacterial infections |
| WO2008127300A2 (en) * | 2006-10-23 | 2008-10-23 | Concert Pharmaceuticals Inc. | Oxazolidinone derivatives and methods of use |
| WO2008085913A1 (en) | 2007-01-04 | 2008-07-17 | Rib-X Pharmaceuticals, Inc. | Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections |
-
2010
- 2010-10-12 UA UAA201205788A patent/UA111145C2/uk unknown
- 2010-10-12 BR BR112012008649A patent/BR112012008649A2/pt not_active IP Right Cessation
- 2010-10-12 US US13/501,220 patent/US20120208857A1/en not_active Abandoned
- 2010-10-12 MX MX2012004282A patent/MX337145B/es active IP Right Grant
- 2010-10-12 AU AU2010307054A patent/AU2010307054A1/en not_active Abandoned
- 2010-10-12 EP EP10823926.0A patent/EP2488175A4/en not_active Withdrawn
- 2010-10-12 SG SG10201406571YA patent/SG10201406571YA/en unknown
- 2010-10-12 CA CA2776310A patent/CA2776310A1/en not_active Abandoned
- 2010-10-12 EP EP16159431.2A patent/EP3095445A1/en not_active Withdrawn
- 2010-10-12 JP JP2012534277A patent/JP2013507443A/ja active Pending
- 2010-10-12 KR KR1020127012191A patent/KR101791709B1/ko active IP Right Grant
- 2010-10-12 WO PCT/US2010/052263 patent/WO2011046905A2/en active Application Filing
- 2010-10-12 NZ NZ599151A patent/NZ599151A/en not_active IP Right Cessation
- 2010-10-12 CN CN2010800462049A patent/CN102573840A/zh active Pending
- 2010-10-12 EA EA201270547A patent/EA022765B1/ru not_active IP Right Cessation
-
2012
- 2012-04-03 IL IL219018A patent/IL219018A/en not_active IP Right Cessation
-
2015
- 2015-02-24 US US14/630,584 patent/US20150165040A1/en not_active Abandoned
- 2015-06-04 JP JP2015113698A patent/JP2015155479A/ja active Pending
-
2016
- 2016-09-27 AU AU2016234893A patent/AU2016234893A1/en not_active Abandoned
-
2017
- 2017-04-12 JP JP2017078885A patent/JP2017141285A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20120208857A1 (en) | 2012-08-16 |
| UA111145C2 (uk) | 2016-04-11 |
| EP2488175A4 (en) | 2013-08-07 |
| AU2016234893A1 (en) | 2016-10-20 |
| IL219018A (en) | 2016-11-30 |
| KR20120099676A (ko) | 2012-09-11 |
| US20150165040A1 (en) | 2015-06-18 |
| AU2010307054A1 (en) | 2012-04-26 |
| CA2776310A1 (en) | 2011-04-21 |
| EA022765B1 (ru) | 2016-02-29 |
| KR101791709B1 (ko) | 2017-10-30 |
| MX337145B (es) | 2016-02-15 |
| EP2488175A2 (en) | 2012-08-22 |
| MX2012004282A (es) | 2012-05-22 |
| EP3095445A1 (en) | 2016-11-23 |
| BR112012008649A2 (pt) | 2021-11-03 |
| JP2017141285A (ja) | 2017-08-17 |
| JP2015155479A (ja) | 2015-08-27 |
| CN102573840A (zh) | 2012-07-11 |
| EA201270547A1 (ru) | 2012-12-28 |
| WO2011046905A2 (en) | 2011-04-21 |
| JP2013507443A (ja) | 2013-03-04 |
| IL219018A0 (en) | 2012-06-28 |
| WO2011046905A3 (en) | 2011-10-20 |
| NZ599151A (en) | 2014-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1231408A1 (zh) | 藥物組合物 | |
| HK1218881A1 (zh) | 藥物組合物 | |
| EP2451274A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| EP2240022A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| EP2373681A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| EP2379077A4 (en) | PHARMACEUTICAL COMPOSITION | |
| GB0902648D0 (en) | Pharmaceutical compounds and compositions | |
| IL219018A0 (en) | Pharmaceutical compositions | |
| GB0919650D0 (en) | Pharmaceutical composition | |
| GB0908317D0 (en) | Pharmaceutical compounds and compositions | |
| GB0800659D0 (en) | Pharmaceutical Compositions | |
| GB0901241D0 (en) | Pharmaceutical compositions | |
| GB0908970D0 (en) | Local pharmaceutical compositions | |
| HU0900010D0 (en) | Improved pharmaceutical composition | |
| GB0902428D0 (en) | Pharmaceutical methods & compositions | |
| GB0921139D0 (en) | Pharmaceutical methods & compositions | |
| GB0903945D0 (en) | Pharmaceutical compounds and compositions | |
| GB0902651D0 (en) | Pharmaceutical compounds and compositions | |
| GB0919055D0 (en) | Pharmaceutical compounds and compositions | |
| GB0908069D0 (en) | Pharmaceutical compounds and compositions | |
| GB0806156D0 (en) | Pharmaceutical compositions | |
| GB0802024D0 (en) | Pharmaceutical compositions | |
| GB0806283D0 (en) | Pharmaceutical compositions | |
| EP2308842A4 (en) | PHARMACEUTICAL COMPOSITIONS |